Skip to main content
HLB Life Science CO.,LTD. logo

HLB Life Science CO.,LTD. — Investor Relations & Filings

Ticker · 067630 ISIN · KR7067630004 LEI · 9884006PTFB20S9PS149 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2025-03-20 Audit Report / Informat…
Country KR South Korea
Listing KO 067630

About HLB Life Science CO.,LTD.

https://www.hlb-lsmc.com/

HLB Life Science is a specialized pharmaceutical and biotechnology firm focused on the development of innovative anti-cancer medications and the manufacturing of medical devices. The company's research and development efforts center on targeted therapies and cell therapies for oncology. In parallel, it develops, manufactures, and distributes in vitro diagnostic (IVD) medical devices and quasi-drugs. The company's portfolio also includes the clinical development of anti-cancer drugs for animals, aiming to provide comprehensive solutions across human and animal health.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from HLB Life Science. It provides the audit opinion (unqualified/proper), key financial data (assets, liabilities, equity, revenue, profit/loss) for the current and previous fiscal years, and identifies the external auditor (Samjong KPMG). While it contains financial data, it is a summary disclosure of the audit results rather than the full annual report (10-K) or a standalone audit report document (AR). In the context of Korean regulatory filings (DART/KIND), this is a standard 'Audit Report Submission' notice, which falls under the category of regulatory filings. FY 2024
2025-03-20 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for HLB Life Science Co., Ltd. for the fiscal year ending December 31, 2024. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. This is a formal, full-year financial audit document, not an earnings release or a summary, and it is distinct from a 10-K (which is a specific US regulatory filing). Therefore, it is classified as an Audit Report. FY 2024
2025-03-20 Korean
신주인수권부사채(해외신주인수권부사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from HLB Life Science regarding the 'Acquisition of Bonds Before Maturity' (specifically Bond with Warrant, BW). It details the specific bond series, acquisition amount, date, and the reason (early redemption request). This type of disclosure regarding capital structure changes and debt management falls under the 'Capital/Financing Update' category.
2025-03-17 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of an upcoming Annual General Meeting (AGM) for HLB Life Science, detailing the date, location, agenda items (such as financial statement approval, director appointments, and remuneration limits), and information regarding electronic voting. This document serves as the official solicitation and notification for shareholders to participate in the meeting, which falls under the Proxy Solicitation & Information Statement category.
2025-03-04 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal notification regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date' (a date where many companies hold their meetings). It explains the company's inability to avoid this date due to audit report timelines. This is a regulatory disclosure regarding corporate governance and meeting logistics, which does not fit into specific categories like AGM-R (presentation materials) or PSI (proxy solicitation). Therefore, it falls under the general regulatory filing category.
2025-03-04 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for HLB Life Science Co., Ltd. It details the meeting date, location, agenda items (financial statement approval, director appointments, etc.), and information regarding electronic voting. This document is a standard proxy statement/notice sent to shareholders to inform them of an upcoming meeting and solicit their participation/votes. In the provided classification schema, this fits best under 'Proxy Solicitation & Information Statement' (PSI).
2025-03-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.